138 related articles for article (PubMed ID: 38087715)
21. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
Belina ME; Driscoll TA; Blanchard SK; Cardones AR
Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
[TBL] [Abstract][Full Text] [Related]
22. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
23. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
24. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development.
Kim DDH; Popradi G; Lepic K; Paulson K; Allan D; Nampoothiri RV; Lachance S; Deotare U; White J; Elemary M; Jamani K; Fraga C; Lemieux C; Novitzky-Basso I; Law AD; Kumar R; Walker I; Schultz KR;
Curr Oncol; 2024 Mar; 31(3):1426-1444. PubMed ID: 38534941
[TBL] [Abstract][Full Text] [Related]
25. Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease.
Oarbeascoa G; Lozano ML; Guerra LM; Amunarriz C; Saavedra CA; Garcia-Gala JM; Viejo A; Revilla N; Acosta Fleitas C; Arroyo JL; Martinez Revuelta E; Galego A; Hernandez-Maraver D; Kwon M; Diez-Martin JL; Pascual C;
Biol Blood Marrow Transplant; 2020 Apr; 26(4):651-658. PubMed ID: 31917270
[TBL] [Abstract][Full Text] [Related]
26. Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature.
Yan WL; Zhao FY; Gu ME; Liu N; Guo XP; Xu XJ
Paediatr Drugs; 2023 Sep; 25(5):577-584. PubMed ID: 37284944
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Koshy AG; Kim HT; Liegel J; Arnason J; Ho VT; Antin JH; Joyce R; Cutler C; Gooptu M; Nikiforow S; Logan EK; Elavalakanar P; Narcis M; Stroopinsky D; Avigan ZM; Boussi L; Stephenson S; El Banna H; Bindal P; Cheloni G; Avigan DE; Soiffer RJ; Rosenblatt J
Blood; 2023 Jun; 141(24):2932-2943. PubMed ID: 36862975
[TBL] [Abstract][Full Text] [Related]
28. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
Wolff D; Gerbitz A; Ayuk F; Kiani A; Hildebrandt GC; Vogelsang GB; Elad S; Lawitschka A; Socie G; Pavletic SZ; Holler E; Greinix H
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1611-28. PubMed ID: 20601036
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.
Oyama T; Matsuda K; Honda A; Maki H; Masamoto Y; Murakami D; Toya T; Sakurai M; Kataoka K; Doki N; Kurokawa M
Int J Hematol; 2023 Feb; 117(2):260-268. PubMed ID: 36251231
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
[TBL] [Abstract][Full Text] [Related]
31. Extracorporeal photopheresis for the treatment of chronic graft versus host disease.
Kansu E; Ward D; Sanchez AP; Cunard R; Hayran M; Huseyin B; Vaughan M; Ku G; Curtin P; Mulroney C; Costello C; Castro JE; Wieduwilt M; Corringham S; Ihasz-Davis A; Nelson C; Ball ED
Hematology; 2022 Dec; 27(1):785-794. PubMed ID: 35802815
[TBL] [Abstract][Full Text] [Related]
32. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
[TBL] [Abstract][Full Text] [Related]
33. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A
Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413
[TBL] [Abstract][Full Text] [Related]
34. A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms.
Kordjazy N; Amini S
Ther Adv Respir Dis; 2024; 18():17534666241232284. PubMed ID: 38504551
[TBL] [Abstract][Full Text] [Related]
35. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
[TBL] [Abstract][Full Text] [Related]
36. Graft-versus-host disease after an outpatient peripheral blood hematopoietic cell transplant using reduced-intensity conditioning: a single-center LATAM experience.
Jaime-Pérez JC; Meléndez-Flores JD; Valdespino-Valdes J; Gómez-De León A; Colunga-Pedraza PR; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D
Expert Rev Hematol; 2024; 17(1-3):77-86. PubMed ID: 38226642
[TBL] [Abstract][Full Text] [Related]
37. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
38. Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
Drobyski WR; Pasquini M; Kovatovic K; Palmer J; Douglas Rizzo J; Saad A; Saber W; Hari P
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1862-8. PubMed ID: 21745454
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
40. Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience.
Vogl UM; Nagayama K; Bojic M; Hoda MA; Klepetko W; Jaksch P; Dekan S; Siersch V; Mitterbauer M; Schellongowski P; Greinix HT; Petkov V; Schulenburg A; Kalhs P; Rabitsch W
Transplantation; 2013 Feb; 95(4):623-8. PubMed ID: 23274967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]